- Home
- TARS vs NFEGP Comparison
TARS vs NFEGP Comparison
Compare TARS & NFEGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$75.73
Company Overview
Basic Information| Metric | TARS | NFEGP |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | TARS | NFEGP |
|---|---|---|
| Price | $75.73 | $440.00 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $89.00 | N/A |
| AVG Volume (30 Days) | ★ 665.2K | 1.1K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $53.89 | $474.95 |
| 52 Week High | $91.53 | $514.99 |
Technical Indicators
Market Signals| Indicator | TARS | NFEGP |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | N/A |
| Support Level | $60.95 | N/A |
| Resistance Level | $79.10 | N/A |
| Average True Range (ATR) | 2.85 | 0.00 |
| MACD | -1.15 | 0.00 |
| Stochastic Oscillator | 11.36 | 0.00 |
Price Performance
Historical Comparison TARS
NFEGP
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.